Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Clinical role
FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Images and patients
Ultrasound · Fetal heart and fetal brain
Key limitation
Keep in mind: The output is a concurrent reading aid; gestational-age, acquisition, patient, and professional-review requirements in the exact labeling govern use.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetal heart and fetal brain Input: Ultrasound echo data acquired with the supported transducers, exam modes, and labeled patient or anatomy scope.
Who uses it?Intended users: Qualified healthcare professionals interpreting fetal ultrasound.
What does the software produce?Output: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
What is its most important limitation?Key limitation: The output is a concurrent reading aid; gestational-age, acquisition, patient, and professional-review requirements in the exact labeling govern use.
Clinical takeaway. Clinical role: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports two standalone performance studies with a 2+1 ground truth procedure as reference standard. Completeness: 5,554 images across 750 patient cases from 7 clinical sites (United States and France); view detection mean sensitivity 96% (Bootstrap CI 0.954-0.966) and mean specificity 99.5% (0.994-0.996). Measurement: 6,024 images across 441 patient cases from 6 clinical sites; all measurements met limits-of-agreement acceptance criteria. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
The exact FDA document reports two standalone performance studies with a 2+1 ground truth procedure as reference standard. Completeness: 5,554 images across 750 patient cases from 7 clinical sites (United States and France); view detection mean sensitivity 96% (Bootstrap CI 0.954-0.966) and mean specificity 99.5% (0.994-0.996). Measurement: 6,024 images across 441 patient cases from 6 clinical sites; all measurements met limits-of-agreement acceptance criteria. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY" … "FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases, including full examination still images, cardiac/brain clip frames and full examination video frames from 7 clinical sites in the United States and France.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports two standalone performance studies with a 2+1 ground truth procedure as reference standard. Completeness: 5,554 images across 750 patient cases from 7 clinical sites (United States and France); view detection mean sensitivity 96% (Bootstrap CI 0.954-0.966) and mean specificity 99.5% (0.994-0.996). Measurement: 6,024 images across 441 patient cases from 6 clinical sites; all measurements met limits-of-agreement acceptance criteria. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY" … "FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases, including full examination still images, cardiac/brain clip frames and full examination video frames from 7 clinical sites in the United States and France.". Read from the exact FDA decision document on 2026-11-14.
Standalone mean sensitivity on the completeness dataset (5,554 images, 750 patient cases): fetal heart and brain view detection 96% (Bootstrap CI 0.954-0.966); 52 fetal heart quality criteria 94.6% (Bootstrap CI 0.939-0.952).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY 7.2.1 FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases," … "Automatic detection of fetal heart and brain views ‘Abdomen’, ‘Four chamber’, ‘LVOT’, ‘RVOT’, ‘Three Vessels’, Transventricular’, ‘Transcerebellar’, ‘Transthalamic’ and ‘Sagittal/profile’: o mean sensitivity of 96% with a Bootstrap CI of (0.954-0.966);". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Standalone mean specificity on the completeness dataset (5,554 images, 750 patient cases) for fetal heart and brain view detection: 99.5% (Bootstrap CI 0.994-0.996); for 52 fetal heart quality criteria: 99.4% (Bootstrap CI 0.994-0.995).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Diagnoly conducted two standalone performance testing: - One for the completeness functionality of FETOLY; - One for the measurement functionality of FETOLY 7.2.1 FETOLY-COMPLETENESS performance study This study was done on a dataset of 5,554 fetal ultrasound images across 750 patient cases," … "Automatic detection of fetal heart and brain views ‘Abdomen’, ‘Four chamber’, ‘LVOT’, ‘RVOT’, ‘Three Vessels’, Transventricular’, ‘Transcerebellar’, ‘Transthalamic’ and ‘Sagittal/profile’: o mean sensitivity of 96% with a Bootstrap CI of (0.954-0.966); o mean specificity of 99.5% with a Bootstrap CI of (0.994-0.996).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
DesignManufacturer-submitted standalone performance testing for fetal ultrasound completeness and measurement functions; not independent clinical validation.
PopulationFetal ultrasound images and sequences in the exact FETOLY validation package.
Scopeexact submission
Tested versionExact FDA submission release; version not separately stated in the public decision material
Samplen=750
IndependenceSponsor or vendor study
K251368
Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K251368 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, dental, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound echo data acquired with the supported transducers, exam modes, and labeled patient or anatomy scope.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The software is installed on hardware connected to an ultrasound machine through HDMI; exact data flow, export, and local interface behavior require acceptance.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Fetoly software installed on a hardware device connected to an ultrasound machine through an HDMI connection, receiving ultrasound images captured by the connected machine in real time. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "To utilize Fetoly, the software needs to be installed on a hardware device which is connected to an Ultrasound Machine through an HDMI connection." … "The software receives ultrasound images captured by the connected Ultrasound Machine in real-time.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Fetoly software installed on a hardware device connected to an ultrasound machine through an HDMI connection, receiving ultrasound images captured by the connected machine in real time. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "To utilize Fetoly, the software needs to be installed on a hardware device which is connected to an Ultrasound Machine through an HDMI connection." … "The software receives ultrasound images captured by the connected Ultrasound Machine in real-time.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The software is installed on hardware connected to an ultrasound machine through HDMI; exact data flow, export, and local interface behavior require acceptance.
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
The software is installed on hardware connected to an ultrasound machine through HDMI; exact data flow, export, and local interface behavior require acceptance.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The output is a concurrent reading aid; gestational-age, acquisition, patient, and professional-review requirements in the exact labeling govern use.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the evidence set; productivity or value claims require local evidence.
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.
exact submission · checked 2026-09-04
Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission
Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.
Non-invasive processing of ultrasound images to detect, measure, and calculate relevant medical parameters of structures and function in patients with suspected disease, with Quality Score feedback.
Modality
Ultrasound
Anatomy
Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
Non-invasive processing of ultrasound images to detect, measure, and calculate medical parameters of structures and function in patients with suspected disease, with Quality Score feedback; the submitted IQS module provides real-time quality scoring for the left ventricle from the four-chamber apical view.
Modality
Ultrasound
Anatomy
Heart; left ventricle from the four-chamber apical view
Non-invasive processing of previously acquired echocardiographic images to detect and measure the left-ventricular wall and calculate left-ventricular function.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.